Abbott Laboratories (Pakistan) Limited (ABOT): Corporate Briefing Notes – By Chase Research

<p></p><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Abbott Pakistan's net sales increased by 13% YoY in CY23 to PKR 55.5 billion compared to PKR 49.3 billion in CY22. The growth was more pronounced in the 9MCY24 period, where net sales rose by 20% YoY, reaching PKR 49.6 billion against PKR 41.2 billion in 9MCY23.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">In CY23, the pharmaceutical segment led with 20% growth to PKR 37.8 billion, while Nutritional declined 8% to PKR 11.4 billion. Diagnostics increased 16% to PKR 4.8 billion, and Others rose 18% to PKR 1.5 billion.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">In CY23, gross margins shrank to 21% from 29% in CY22, mainly due to revision of pro...